Company research / TLRY

Tilray Brands, Inc. (TLRY)

CIK 0001731348 · Nasdaq · Medicinal Chemicals & Botanical Products

  • Sector Manufacturing
  • Fiscal year ends around May 31

For the year ended 2026-05-31, Tilray Brands, Inc. reported revenue of $915.45M. Revenue grew 11.5% from the prior annual period. Over the twelve months to 2026-08-31, revenue was $963.10M.

Key ratios (year ended 2026-05-31)

28.4%
Gross margin
-6.9%
Operating margin
-13.3%
Net margin
-7.5%
Return on year-end equity
11.5%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 10-Q (quarterly report) · 2026-10-08

Headquarters locality: Nanaimo · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-08-31 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Stock splits: 1-for-10, first reflected in a filing dated 2026-01-08. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

Period endedTTM to
2026-08-31
2026-05-312025-05-312024-05-312023-05-312022-05-312021-05-312020-12-312020-05-312019-12-312019-05-31
Revenue$963.10M$915.45M$821.31M$788.94M$627.12M$628.37M$513.09Mn/a$405.33Mn/a$179.30M
Cost of Revenue$682.62M$655.01M$580.74M$565.59M$480.16M$511.56M$389.90Mn/a$309.27Mn/a$135.79M
Gross Profit$280.48M$260.44M$240.57M$223.35M$146.96M$116.82M$123.18Mn/a$96.05Mn/a$43.51M
R&D Expense$409.0K$361.0K$284.0K$635.0K$682.0K$1.52M$830.0Kn/a$1.92Mn/a$1.05M
Operating Income-$89.17M-$63.03M-$2.28B-$174.75M-$1.37B-$610.40M-$132.17Mn/a-$104.01Mn/a-$138.93M
Depreciation & Amortizationn/an/an/an/an/a$154.59M$67.83Mn/a$35.67Mn/a$17.21M
EBITDAn/an/an/an/an/a-$455.81M-$64.34Mn/a-$68.34Mn/a-$121.72M
Net Income-$164.22M-$121.40M-$2.19B-$244.98M-$1.45B-$476.80M-$367.42Mn/a-$102.54Mn/a-$25.04M
EPS (Diluted)n/a-$1.09-$24.56-$3.30-$2.35-$0.99-$1.36n/a-$0.47n/a-$0.18
Total Assets$2.33B$2.33B$2.07B$4.22B$4.31B$5.45B$6.03B$945.95M$1.74B$896.33Mn/a
Total Liabilities$721.28M$733.14M$584.75M$778.49M$977.32M$1.01B$1.56B$572.05M$463.00M$611.06Mn/a
Long-Term Debtn/an/an/an/an/a$185.70M$204.11Mn/a$94.03Mn/an/a
Shareholders' Equity$1.62B$1.61B$1.51B$3.44B$3.32B$4.40B$4.46B$373.90M$1.25B$285.27Mn/a
Cash & Equivalents$214.96M$225.98M$221.67M$228.34M$206.63M$415.91M$488.47M$189.70M$360.65M$96.79Mn/a
Operating Cash Flow-$84.34M-$69.14M-$94.60M-$30.91M$7.91M-$177.26M-$44.72Mn/a-$100.63Mn/a-$42.05M
Capital Expendituresn/an/a$32.92M$29.25M$20.80M$34.06M$38.87Mn/a$98.79Mn/a$155.75M
Free Cash Flown/an/a-$127.52M-$60.15M-$12.89M-$211.33M-$83.59Mn/a-$199.41Mn/a-$197.80M
Shares Outstanding144.94M131.68M1.06B831.93M656.66M532.67M446.44Mn/an/an/an/a
Weighted Average Diluted Sharesn/a111.83M89.03M74.26M617.98M481.22M269.55Mn/a216.16Mn/a203.46M
EPS (Basic)n/a-$1.09-$24.56-$3.30-$2.35-$0.99-$1.36n/a-$0.47n/a-$0.18

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView